Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer
1. Progression-free survival was longer for patients receiving tiragolumab with atezolizumab as...
Read MoreMay 24, 2022
1. Progression-free survival was longer for patients receiving tiragolumab with atezolizumab as...
Read MoreMay 24, 2022
1. The adebrelimab group had an improved overall survival, higher objective response rate and an...
Read MoreMay 20, 2022
Click to read this study in the Journal of Clinical Oncology.
Read MoreMay 19, 2022
Click to read this study in Journal of Clinical Oncology.
Read MoreMay 18, 2022
1. Complete clinical response at 6 months was similar in both the topical imiquimod and surgery...
Read MoreMay 17, 2022
1. The median progression free survival for all cancer-types was 2.8 months. 2. Most of the...
Read MoreMay 12, 2022
1. A combination of androgen deprivation therapy, docetaxel, and abiraterone (“triplet therapy”)...
Read MoreMay 10, 2022
1. Patients with resectable non-small cell lung cancer (NSCLC) receiving neoadjuvant nivolumab in...
Read MoreMay 10, 2022
1. Disease-free survival was not impacted by the order in which chemoradiotherapy CRT and systemic...
Read MoreMay 5, 2022
Click to read this study in The Lancet Oncology.
Read MoreMay 4, 2022
Liver cancer is the third-highest cause of cancer-related deaths worldwide, and incidence of...
Read MoreMay 4, 2022
1. Muscle-strengthening activities (MSA) were associated with a lower risk of cardiovascular...
Read MoreMay 4, 2022
Click to read this study in The Lancet Oncology.
Read MoreMay 4, 2022
1. Patients who underwent segmentectomy reported a significantly greater 5-year overall survival...
Read MoreMay 3, 2022
1. The median follow-up period for health-related quality-of-life (HRQOL) outcomes analyses was...
Read MoreMay 3, 2022
1. Event-free survival and median overall survival were significantly longer in the combination...
Read MoreApr 30, 2022
1. This population-based cohort study demonstrated that there was a 20.7% reduction in cancer care...
Read MoreApr 29, 2022
1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher...
Read MoreApr 28, 2022
Click to read this study in The Lancet Oncology.
Read More